GSE235066 carboplatin 4 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE235066_carboplatin_4_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE235066_carboplatin_4_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE235066_carboplatin_4_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE235066_carboplatin_4_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 1

Gene

growth arrest specific 5

Gene

THAP9 antisense RNA 1

Gene

gametogenetin binding protein 2

Gene

small nucleolar RNA host gene 12

Gene

zinc finger protein 883

Gene

long intergenic non-protein coding RNA 641

Gene

long intergenic non-protein coding RNA 294

Gene

nicotinamide phosphoribosyltransferase pseudogene 1

Gene

zinc finger protein 271, pseudogene

  • Gene

    small nucleolar RNA host gene 1


  • Gene

    growth arrest specific 5


  • Gene

    THAP9 antisense RNA 1


  • Gene

    gametogenetin binding protein 2


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    zinc finger protein 883


  • Gene

    long intergenic non-protein coding RNA 641


  • Gene

    long intergenic non-protein coding RNA 294


  • Gene

    nicotinamide phosphoribosyltransferase pseudogene 1


  • Gene

    zinc finger protein 271, pseudogene

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.